How Cas9 Finds One Letter Out of Three Billion

The human genome is roughly 3.2 billion base pairs. Cas9 needs to find one specific sequence in that entire library, cut both strands of the double helix there, and not cut anywhere else. The precision required is extraordinary.

Here's how it works.

You design a "guide RNA" (gRNA) — about 20 nucleotides long — that matches the target DNA sequence. This guide RNA binds to Cas9 and gives it a destination. Cas9 then scans along the DNA looking for its target. It doesn't read every base pair sequentially — that would be impossibly slow. Instead, it uses a shortcut: it looks for a short 3-letter sequence called a PAM site (Protospacer Adjacent Motif). For SpCas9, this is the sequence NGG, where N can be any nucleotide.

Whenever Cas9 encounters an NGG, it stops and checks whether the 20 bases upstream match its guide RNA. If they match, it locks on, unwinds the DNA, and positions both cutting domains (RuvC and HNH) to nick one strand each. Both strands cut simultaneously, producing what's called a double-strand break.

A double-strand break is one of the most dangerous events a cell can experience. Left unrepaired, it can cause cell death. Cells have evolved two main repair pathways: NHEJ (Non-Homologous End Joining) and HDR (Homology-Directed Repair).

NHEJ is fast and sloppy — it glues the broken ends back together, often making small insertions or deletions (indels) in the process. Those indels can knock out a gene entirely, which is useful if you want to disable something.

HDR is slower but precise — if you provide a DNA template along with the cut, cells can use it to copy in a new sequence. This is how you introduce specific edits, not just break things.

The beauty of the system: the only thing you need to change to target a different gene is the 20-nucleotide guide RNA sequence. The Cas9 protein stays the same. That's why CRISPR spread so fast after 2012 — the programmable part is cheap and easy to synthesize.

How Cas9 Finds One Letter Out of Three Billion

// COMMENTS

ON THIS PAGE